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Received 11 March 2004; accepted 2 August 2004AbstractSince the discovery in the 1970s that dendritic abnormalities in cortical pyramidal neurons are the most consistent pathologic correlate of
mental retardation, research has focused on how dendritic alterations are related to reduced intellectual ability. Due in part to obvious ethical
problems and in part to the lack of fruitful methods to study neuronal circuitry in the human cortex, there is little data about the
microanatomical contribution to mental retardation. The recent identification of the genetic bases of some mental retardation associated
alterations, coupled with the technology to create transgenic animal models and the introduction of powerful sophisticated tools in the field of
microanatomy, has led to a growth in the studies of the alterations of pyramidal cell morphology in these disorders. Studies of individuals with
Down syndrome, the most frequent genetic disorder leading to mental retardation, allow the analysis of the relationships between cognition,
genotype and brain microanatomy. In Down syndrome the crucial question is to define the mechanisms by which an excess of normal gene
products, in interaction with the environment, directs and constrains neural maturation, and how this abnormal development translates into
cognition and behaviour. In the present article we discuss mainly Down syndrome-associated dendritic abnormalities and plasticity and the
role of animal models in these studies. We believe that through the further development of such approaches, the study of the microanatomical
substrates of mental retardation will contribute significantly to our understanding of the mechanisms underlying human brain disorders
associated with mental retardation.
# 2004 Elsevier Ltd. All rights reserved.Contents
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The biological bases for mental retardation are poorly
understood, but defects in neuronal network formation or in
properties of brain plasticity likely contribute to the
cognitive impairment. Down syndrome (DS) is the most
common genetic disorder associated with mental retardation
(Hassold and Jacobs, 1984; Mastroiacovo, 2002) and its
phenotypic characteristics are believed to stem from the
overexpression of a set of genes on human chromosome 21.
Thus, studies of the DS population provide a rare
opportunity to examine relationships between cognition,
genotype and brain neurobiology. In patients with DS,
mental retardation is moderate and the intelligence
coefficient ranges between 20 and 80 (Anneren and
Pueschel, 1996). The rate of cognitive development tends
to slow as children with DS grow older so that the brain
undergoes a progressive postnatal degenerative process.
The neuropathological correlates of these impairments
are still under intensive investigation. In subjects with DS,
brain size and weight are moderately reduced at birth.
Specific brain areas exhibit an immature gyral pattern,
neocortical laminar formation is irregular and myelination
of cortical fibres is delayed (Kemper, 1988; Golden and
Hyman, 1994; Wisniewski and Kida, 1994). Data obtained
from studies that have utilized functional neuroimaging
techniques have expanded our knowledge of the neuroana-
tomical basis of brain malfunctioning in DS brains and
provided initial clues as to the specific defects that occur
during neural development. The advent of in vivo structural
brain imaging will not only help researchers identify which
brain structures are implicated in specific neurobehavioural
conditions but also may discover individual variations
among persons with the same genetic defect. Using
magnetic resonance imaging (MRI), Raz et al. (1995)
showed that young adult DS subjects have reduced volumes
of cerebral and cerebellar hemispheres, ventral pons,
mammillary bodies, and hippocampal formation, even after
adjustment for body size. In contrast, the parahippocampal
gyrus is enlarged and frontal lobe volumes are disproportio-
nately smaller in DS (Pinter et al., 2001). Functional
imaging with positron emission tomography (PET) showscerebral metabolic rates for glucose in young DS adults, with
fewer significant correlations in different brain regions than
in controls, suggesting that functional connections between
brain circuit elements are reduced leading to dysfunctional
circuitry in adults (Shapiro et al., 1992).
At the microscopic level, neuronal density is decreased in
distinct regions of DS brains, including the cochlear nuclei,
cerebellum, hippocampus, basal forebrain, the granular layers
of the neocortex and areas of the brainstem. In the neocortex,
neuronal morphology is abnormal and neuronal orientation is
aberrant (reviewed in Flo´rez, 1992). Other studies have
reported reductions in cortical width, abnormal cortical
lamination patterns, altered dendritic arbours and dendritic
spines, aberrant electrophysiological properties of mem-
branes, reduced synaptic density and abnormal synaptic
morphology in DS foetuses (Becker et al., 1986, 1991; Marin-
Padilla, 1976; Suetsugu and Mehraein, 1980, see also Section
1.1). Some of these alterations may be related to an abnormal
development of the nervous system during pre- and post-natal
life. However, it is difficult to attribute the cognitive
alterations in DS to a simple reduction of brain size or
neuronal density. In fact, neuronal cell structure does not
correlate with differences in brain size. Instead, different
aspects of neuronal cell structure such as the size of the basal
dendritic arbours, their branching structure, and spine density
may vary independently (see Elston, 2003a for a review).2. Dendritic pathology in Down syndrome
Neural mechanisms underlying mental retardation may
include defects in the formation of neuronal networks and/or
in information processing aspects of brain plasticity.
Dendritic pathology is a consistent feature and substrate
of mental retardation across multiple conditions suggesting
that dendritic abnormalities are an index of major neuronal
disruption (reviewed in Kaufmann and Moser, 2000) and
that dendritic architecture determines the nature of a
neurone’s inputs and its role in cortical circuitry (Friedlander
et al., 1982; Bacon and Murphey, 1984). In DS, the
pathogenesis of dendritic abnormalities is distinctive and
appears to correlate to some extent with cognitive profile.
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the brain circuitry could contribute to observed dendritic
abnormalities in DS, with serious consequences on the
cognitive abilities. However, if the severity and extent of
dendritic alterations correlates with cognitive function, then
DS subjects with moderate mental retardation should show
mild dendritic abnormalities; likewise, if dendritic abnorm-
alities are a sign of global cognitive dysfunction, they should
be observed in many other syndromes associated with
mental retardation, and dendritic alterations should parallel
defects in neuronal maturation and/or decline in cognition.
Moreover, these alterations may depend on different cellular
mechanisms so that in DS, neurons may not achieve the
structural complexity observed in normal children, or
alternatively they may undergo greater dendritic retraction
during maturation. Good candidate genes exist on chromo-
some 21, whose altered function could account for both
possibilities (see the following).
2.1. How do dendritic arbourisations develop in
Down syndrome brains?
It has been argued that DS persons start their lives with an
apparently normal neuronal architecture that progressively
degenerates. Thus, normal or even increased branching in
the DS foetus and newborn contrasts with reduced dendrites
and degenerative changes in older children with DS. Becker
et al. (1986) showed that in infants with DS younger than 6
months, dendritic branching and length in both apical and
basilar dendrites were greater than in normal infants. During
the peak period of dendritic growth and differentiation,
quantitative analysis of dendrites in layer IIIc pyramidal
neurons of prefrontal cortex (prospective area 9) of the
brains of 2.5-month-old infants revealed no significant
differences in dendritic differentiation between euploid and
DS cases (Vuksic et al., 2002). In contrast, basilar dendrites
of cortical pyramidal neurons are shorter than normal in DS
subjects older than 4 months (Takashima et al., 1981). These
findings suggest that children with DS begin their lives with
morphologically normal layer III pyramidal neurons and
that pathologic changes in key prefrontal input–output
neuronal elements occur after 2.5 months of postnatal age.
Subsequent to this age, there is a steady decrease so that in
subjects with DS older than 2 years, these parameters are
reduced relative to controls especially in apical dendrites
(Becker et al., 1986).
In adults with DS, cross-sectional studies demonstrate
marked reductions in dendritic branching and length, and in
spine density (Takashima et al., 1989; Becker et al., 1991).
Degenerative neuronal changes are also associated with
dendritic abnormalities. Two other reports on pyramidal
neurons in parietal cortex (Schulz and Scholz, 1992) and on
non-pyramidal neurons in motor cortex (Prinz et al., 1997)
support these findings. In cases of aged DS brains that do not
show Alzheimer disease (AD)-like pathology, the number of
spines in the middle and distal segments of apical dendritesof pyramidal neurons in cingulate cortex and in hippocam-
pus are reduced; these changes are more severe in CA1 of
those DS cases with AD (Suetsugu and Mehraein, 1980;
Ferrer and Guillotta, 1990).
Reductions in the size and dendritic length of pyramidal
cells also affect the total number of spines (Fig. 1). Dendritic
spines are thin protrusions emerging from dendrites that are
the sites of most excitatory synapses in the cerebral cortex.
Spines are believed to increase the connectivity of neurons,
to provide chemical compartmentalisation for calcium and
proteins, and to participate in neural computation (Sorra and
Harris, 2000). Recent studies show that dynamic changes in
the structure and shape of spines are important for synaptic
function (Harris, 1999; Yuste and Bonhoeffer, 2001). Since
each spine receives at least one excitatory glutamatergic
synapse (reviewed in DeFelipe and Farin˜as, 1992; Elston
and DeFelipe, 2002), decreases in spine density and number
may impair the ability of pyramidal neurons to integrate
inputs, and reveal an impaired activity-dependent neural
plasticity. The size and branching pattern in the dendritic
arbours of pyramidal neurons relate to a number of
physiological and biochemical properties of these cells
including (1) compartmentalisation of processing of cortical
neurons, and (2) synaptic plasticity, a process that refers to
the changes in the strength of synaptic function, and includes
both short-term changes in the strength or efficacy of
neurotransmission as well as longer term changes in the
structure and number of synapses (for a review see Elston et
al., 2001). Thus, changes in the number of spines in the
dendritic arbours of neurons may influence both cellular and
systems cortical function (see Elston and DeFelipe, 2002;
Elston, 2003b; Jacobs and Scheibel, 2002, for reviews).
Dendritic spines are heterogeneous with regard to their
structure, stability and function (see Kasai et al., 2003;
Benavides-Piccione et al., 2004). Spines with large heads are
stable, express large numbers of AMPA-type glutamate
receptors, and contribute to strong synaptic connections. In
contrast, spines with small heads are motile and unstable and
contribute to weak or silent synaptic connections. These
structure–stability–function relationships suggest that large
and small spines are ‘memory spines’ and ‘learning spines’,
respectively (Kasai et al., 2003). Glutamate receptors turnover
rapidly, indicating that spine structure and the underlying
organisation of the actin cytoskeleton are likely major
determinants of fast synaptic transmission and provide a
physical basis for memory in cortical neuronal networks.
Interestingly, initial studies of infants with DS demonstrated
that spines are sparse, small and had short stalks intermingled
with unusually long spines in motor cortex (Marin-Padilla,
1972, 1976; Purpura, 1974). The decreased density and long
and tortuous profile of spines from DS brains are typical
features of spine dysgenesis (Marin-Padilla, 1972). In DS,
spine dysgenesis is associated with dendritic vacuolisation
and neuronal necrosis (Marin-Padilla, 1976). Therefore,
dendritic spine dysgenesis in DS may indicate an early
postnatal degenerative process. Takashima et al. (1981) also
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Fig. 1. (A) Low-power photomicrograph of layer III pyramidal cells in a 150-mm thick slice taken from the frontal cortex of a wild type mouse that were
injected with Lucifer Yellow and processed for a light-stable diaminobenzidine reaction product. (B) Higher magnification showing layer III pyramidal cells of
the frontal cortex. (C) High power photo of a horizontally projecting dendrite to illustrate the density and distribution of individual dendritic spines along its
length. Note the clear detail of individual dendritic spines. Scale bar: 400 mm in (A), 60 mm in (B), and 10 mm in (C).raised this possibility in one of the largest studies with respect
to sample size that analysed neurons of the visual cortex in
foetuses, neonates and infants with DS.
In view of these reports it is likely that the dendritic
alterations in DS are the result of deficits in neurodevelop-
ment. Dendritic development is a sequential process in
which generation, elongation, and retraction of dendritic
branches and spines are the result of the interactions between
intrinsic genetic programs and external modulators (e.g.,
neurotransmitters) (see Kaufmann, 1999; Weitzdoerfer et
al., 2001). Dendritic growth initially follows genetic dictates
but later becomes modified by levels and patterns of activity
(Bartlett and Banker, 1984) in both developing (Kossel et al.,
1995; Segal, 1995) and mature systems in response to
numerous manipulations, including denervation (Parnavelas
et al., 1974), long-term potentiation (LTP) (Buchs and
Muller, 1996; Sorra and Harris, 1998), and environmental
stimulation (Comery et al., 1996; Jones et al., 1997). With
each developmental stage, the expression of a set of
dendritic proteins (Petit et al., 1988; Kaufmann et al., 1997),
neurotransmitters and growth factors that influence the
progression of dendritic development changes. Spines are
very dynamic structures; their size, shape and number
change throughout life. During development, dendritic
protrusions start out as filopodia, which search out contacts
with synaptic terminals and then mature into adult spines
(Ziv and Smith, 1996). In adults, modulation of the number
and shape of spines is associated with synaptic plasticity
(Engert and Bonhoeffer, 1999; Maletic-Savatic et al., 1999;
Lendvai et al., 2000; Toni et al., 1999) and learning (Comeryet al., 1996). Spine abnormalities and changes in the
numbers of spines in the dendritic arbours of neurons are
commonly reported in neurological disorders such as mental
retardation (Purpura, 1974; Geinisman et al., 1992; Dierssen
et al., 2003). In DS, pyramidal neurons are morphologically
normal at birth, but the number of dendrites and spines
decrease steadily in postnatal life. Thus, the genetic defect
associated with dendritic disturbances in DS may disrupt
signalling pathways and/or modulators of dendritic devel-
opment (Table 1, see also Section 1.2).
Changes in synaptic function and remodelling of synaptic
networks induced by specific patterns of activity are believed
to represent key mechanisms for information processing
(Stepanyants et al., 2002). Thus, the identification and
functional analyses of the gene products involved in DS are
critical not only for a better understanding of the causes of
mental retardation but also for identifying the cellular and
molecular mechanisms contributing to cognitive function.
2.2. Genetic control of dendritic maturation:
what is wrong in Down syndrome?
Dendritic alterations in DS may be the consequence of
higher levels of proteins coded for by three copies of genes
on human chromosome 21 (Table 1). Specific genetic loci,
especially those in the DS critical region (DSCR), are
primary candidates for regulating the abnormal development
and maturation of the DS brain (Delabar et al., 1993;
Shapiro, 1999). However, genes located on other chromo-
somes are also involved. The enormous amount of new
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Table 1
HSA21 genes involved in brain development and synaptic plasticity
SIM2 (single-minded homolog 2) Synchronized cell division and establishment of (Drosophila) proper cell lineage
DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation kinase) Expressed during neuroblast proliferation and believed to regulate of
cell-cycle kinetics. Possible role in neuritogenesis and neural plasticity
GART (phosphoribosylglycinamide formyltransferase) Expressed during prenatal development of the cerebellum
PCP4 (Purkinje cell protein 4) Expressed exclusively in the brain most abundantly in the cerebellum
DSCAM (Down syndrome cell adhesion molecule) Role in axonal outgrowth
GRIK1 (glutamate receptor) Expressed in pyramidal cells of the cortex in fetal and early postnatal life
and in adult
APP (amyloid beta (A4) precursor) Involved in plasticity, neurite outgrowth, and Alzheimer disease
S100B (neural) (S100 calcium binding protein beta) Stimulates glial proliferation
SOD1 (superoxide dismutase 1) Role in apoptosis in fetal DS neural cultures
DSCR1 (Down syndrome critical region 1) Role in LTP/LTD
ITSN (intersectin) Role in endocytosismolecular and biological data that has developed for human
chromosome 21 as a result of the human genome initiative
(Hattori et al., 2000a,b) has sped up the understanding of the
molecular and cellular basis of mental retardation, and will
have an immediate impact on the study of the genetic aspects
of DS by providing a comprehensive catalogue of the genes
on human chromosome 21. The gene content of chromo-
some 21 is now estimated to be 329, including 165
experimentally confirmed genes, 150 gene models based on
expressed sequence tag databases and 14 computer
predictions (see http://www-eri.uchsc.edu). Several anon-
ymous loci for monogenic disorders and predispositions for
common complex disorders have also been mapped to
human chromosome 21. However, the functions of most of
these genes remain largely unknown, as does their
contribution, if any, to DS. The phenotypic consequences
of increased gene dosage depend, in part, on the biological
function of the gene product itself (e.g., enzyme, structural
protein, transcription factor, intracellular signalling mole-
cule, cell surface marker, receptor subunit, etc.). To date,
only a few human chromosome 21 encoded genes have been
used to make transgenic mice (see Dierssen et al., 1999,
2001, 2003; Pritchard and Kola, 1999 for reviews).
The selection of candidate genes is based on their
location in the chromosomal region that is considered
critical for the development of the syndrome, the previous
knowledge of the functions of the proteins that they encode,
or their spatio-temporal pattern of expression. The recent
creation of a high-resolution expression ‘atlas’ of human
chromosome 21 is facilitating the understanding of gene
function and of the pathogenetic mechanisms in Down
syndrome (Gitton et al., 2002; Reymond et al., 2002). The
spatial and temporal expression patterns must be linked to
structural and physiological changes, information that will
shed light on the roles of individual genes in specific
developmental pathways.
Multiple molecular cascades are likely to be involved in
normal dendritic and spine maturation (see Elston and
DeFelipe, 2002; Harris, 1999; Horner, 1993; Shepherd, 1996
for reviews). Here we focus on some of what we consider to
be the most salient molecular mechanisms that may bealtered in DS individuals, resulting in specific DS associated
neuropathology. DYRK1A, is a serin-threonin kinase located
on HSA21, has been reported to influence neurogenesis and
dendritic development. Yang et al. (2001) showed that
overexpression of a kinase-deficient form of DYRK1A
attenuates the neurite outgrowth induced by a neurogenic
factor in immortalized hippocampal cells. In addition, the
expression pattern of Dyrk1A mRNA and protein at early
embryonic ages in mice suggests that it participates in the
transition of neuroepithelial cells from proliferating to
neurogenic divisions (Hammerle et al., 2002). Dyrk1A also
regulates the development of dendritic trees of neurones and
modulates the activity of the c-AMP response element-
binding protein (CREB), which participates in signal
transduction pathways involved in synaptic plasticity and
neuronal differentiation (Hammerle et al., 2003). Finally,
DYRK kinases may modulate dendrite development by
regulating vesicle trafficking which is dependent on
Dynamin (DYN1), a GTPase putative substrate of
DYRK1A, that plays a fundamental role in synaptic vesicle
recycling, clathrin-mediated endocytosis, intracellular
membrane trafficking (see Torre et al., 1994 for a review)
and neurite outgrowth (Chen-Hwang et al., 2002; Kim et al.,
1997). DYRK1A is transported through the growing
dendritic tree where it co-localizes with DYN1 (Hammerle
et al., 2003). Taken together these data suggest a relevant
function for Dyrk1A during neuronal development, related
to proliferation and differentiation. Interestingly, reduced
Dyrk1A dosage in mice leads to a decrease in brain size,
with no obvious alterations in the lamination and anatomy of
the cerebral cortex (Fotaki et al., 2002). In Dyrk1A haplo-
insufficient mice, neuropil size is decreased in some brain
areas. In particular, pyramidal cells in Dyrk1A+/ layer III
are considerably smaller, less branched and less spinous than
those in wild type animals, suggesting that Dyrk1A is
involved in the determination of the pyramidal cell
phenotype and circuit structure (Benavides-Piccione et
al., submitted).
Down syndrome cell adhesion molecule (DSCAM) is
overexpressed in DS brains. The mechanism by which
DSCAM is involved in the pathogenesis of mental
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neurite outgrowth. A lethal mutation in the Drosophila
Dscam specifically perturbs segregation of axonal branches
(Wang et al., 2002). How does the mutation differ from
excess expression of this protein? Axon bifurcation is
essential for efficient innervation of multiple targets and
results in the formation and divergent segregation of the
sister branches.
Amyloid deposition in the form of the Ab peptide is
detected as early as at 21 gestational weeks in DS (Teller et
al., 1996), which coincides with normal initial cortical
dendritic growth (Huttenlocher, 1990). Inflammatory
responses associated with Ab deposition in senile plaques
in AD include production of cytokines (Dickson, 1997),
which may operate as negative modulators of dendritic
growth and maintenance in DS.
Finally, dendritic spines are extremely motile, provi-
ding a structural mechanism for synaptic plasticity
(Crick, 1982). As the major cytoskeletal components in
dendritic spines, actin filaments provide the basic
structural scaffolding of spines (Hayashi et al., 1996;
Penzes et al., 2003) and are likely responsible for the
changes in the shape of spines. Among actin-regulatory
components of spines, drebrin is co-localized with actin
filaments at dendritic spines in high-density long-term
primary cultures of rat cerebral cortex neurons. Drebrin, an
actin-binding protein, is thought to regulate assembly and
disassembly of actin filaments (Asada et al., 1994), thereby
changing the shape of spines. In fact, when the actin-
binding domain of drebrin is deleted, the protein
distributes in both spines and dendritic shafts, indicating
that the selective accumulation of drebrin in the spines
requires its actin-binding activity (Hayashi and Shirao,
1999). In the early second trimester, levels of drebrin and
the synaptosomal associated proteins alpha SNAP and
SNAP 25 are lower in DS brains (Shim and Lubec, 2002).
Thus, spine motility and plasticity may be affected in DS
brains. Other genes that may be involved in central nervous
system development or neural functions related to synaptic
plasticity are listed in Table 1.3. The neural phenotype in animal models for
Down syndrome: what do we know?
A better understanding of DS neuronal networks will
enhance the understanding of cognitive processes, and to
achieve this goal animal models have enormous potential to
elucidate mental retardation mechanisms that may be acting
in humans. Studies with the various trisomy mouse models
at different developmental stages can recreate certain
conditions that result in abnormal learning capabilities in
DS. Experimental models for human disease have greatly
advanced our knowledge of basic brain mechanisms,
psychiatric conditions and neurological diseases. The use
of transgenic techniques to model human disease has led tomajor advances in our understanding of pathogenic
mechanisms, but has also highlighted the limitations of
conventional transgenic methodology for the production of
accurate animal models, and the difficulties associated with
modelling human pathophysiology in mice (Gerlai, 1996;
Crawley and Paylor, 1997; Rogers et al., 1997). We have to
bear in mind the limitations of conventional transgenic
methodology: the presence of compensatory processes (up-
or downregulation of gene products) and resulting secondary
phenotypical changes, the fact that null-mutant organism
might not only lack the product of a single gene but might
also possess a number of developmental, physiological, or
even behavioural processes that have been altered to
compensate for the effect of the null mutation, and the
presence of an array of complex phenotypical changes that
might not be directly related to the function of the gene of
interest.
The varied approaches used to study the consequences of
increased gene dosage in DS and to investigate phenotype/
genotype relationships of HSA21 genes in mice (see Cairns,
2001; Galdzicki and Siarey, 2003 for review) are: (1)
transgenic animals overexpressing single or combinations of
genes, (2) transgenic mice with large foreign DNA pieces
introduced on yeast artificial chromosomes (YACs) or
bacterial artificial chromosomes into mice (Smith et al.,
1995, 1997), (3) mouse models that carry all or part of
MMU16, which has regions of conserved homology with
HSA21 and (4) chimaeric mice that carry a fragment of
human chromosome 21 (Tomizuca et al., 1997).
Single gene transgenesis has been used as a tool to
understand the molecular basis of DS. Although over-
expressing a single gene will not be a model of DS, the value
of single gene transgenesis is to identify genes related to
specific pathophysiological features. Studying transgenic
mice that overexpress single genes, either with their own
genomic regions for gene regulation and expression, or with
heterologous promoter sequences that drive the expression
of the genes in specific tissues, allows the determination of
the contribution of each gene to the phenotype.
The interest in trisomic models lies in modelling and
characterizing DS (or a part of it) and in testing therapeutic
strategies. Trisomy models have the advantage in that they
overexpress orthologues of multiple genes located on
HSA21, permitting the study of how multiple genes interact
to control each other at the level of transcription.
Orthologous genes are frequently linked in similarly
conserved chromosomal segments in the mouse and human
genomes (Mouse Genome Database: http://www.informa-
tics.jax.org). For this reason aneuploidy for regions of the
mouse genome that are conserved on human chromosomes
allows for the study of the effects of over (or under)
expression of multiple genes. HSA21 shows conserved
syntenies to mouse chromosomes (MMU) 16, 17 and 10
(Hattori et al., 2000a,b). Comparative mapping between
mice and humans shows that HSA21 shares a large region of
genetic homology with MMU16. Based on this rationale,
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model for DS. The first mice used had three copies of the
complete MMU16 (Ts16 mice). Ts16 mice exhibit some
characteristics of DS (Miyabara et al., 1984; Gearhart et al.,
1986). However, Ts16 mice die in utero precluding the study
of many of the major features that occur postnatally (e.g.,
mental retardation, Alzheimer’s disease neuropathology). In
addition, only 129 of the 731 genes on MMU16 correspond
to HSA21, and thus Ts16 mice are not trisomic for some
HSA21 genes and have three copies of other genes that are
not implicated in the pathogenesis of DS. In spite of all these
shortcomings, Ts16 mice do model some of the character-
istic features of DS. These features include: (1) cardiac
malformations, which are associated with the Down
syndrome critical region 1 (DSCR1) gene, encoding a
regulatory protein in the calcineurin/NFAT signal transduc-
tion pathway (Lange et al., 2004), (2) craniofacial and ocular
malformations including a reduction of periorbital con-
nective tissue and micro-ophtalmia (Oster-Granite, 1986)
and alterations in the development of the cerebellum,
hippocampus and cortical plate (Grausz et al., 1991). The
overall reduction in cortical neurons in TS16 is thought to
arise from abnormalities in neurogenesis, a failure of brain-
derived neurotrophic factor-dependent neuron survival and
increased caspase-dependent apoptosis (Haydar et al., 1996,
2000; Bambrick and Krueger, 1999; Dorsey et al., 2002).
Mouse Ts16 hippocampal neurons demonstrate slowed
depolarisation of the AP, reflecting a reduced TTX-sensitive
voltage-dependent Na+ current and a reduced density of Na+
channels. The dihydropyridine-sensitive, voltage-dependent
Ca2+ current is increased, reflecting an increased density of
L-type Ca2+ channels. Abnormal Na+ and Ca2+ channel
densities are not due to reduced transcription of the main
channel subunits and thus likely reflect post-translational
defects. The abnormalities in Ts16 hippocampal neurons are
opposite in direction to abnormalities in Ts16 DRG neurons,
indicating that there is not a common membrane electrical
abnormality in all Ts16 neuronal types. The cell-type
differences may reflect, however, a common defect in signal
transduction possibly involving channel phosphorylation
(see Galdzicki and Siarey, 2003). Selective failure of BDNF-
dependent survival in cultured hippocampal neurons from
the Ts16 mouse has been described. This failure is
accompanied by overexpression of a truncated, kinase-
deficient isoform of the BDNF receptor tyrosine receptor
kinase B (NTRK2). Adenovirus-mediated introduction of
exogenous full-length NTRK2 into Ts16 neurons fully
restored BDNF-dependent survival, whereas exogenous
truncated NTRK2 expression in normal, euploid neurons
reproduced the Ts16 BDNF signalling failure. Thus, the
failure of Ts16 neurons to respond to BDNF is caused by
dysregulation of NTRK2 isoform expression. Such a
neurotrophin signalling defect could contribute to altered
late LTP, thus leading to altered structural properties of the
dendritic spines with consequences in neural plasticity and
possibly in long-term memory storage.The Ts16 mice present altered corticogenesis (Haydar
et al., 1996). Slowed tangential expansion of the
neuroepithelium in Ts16 resulted in a reduction of final
telencephalic size and is predicted to decrease the number
of radial cortical units in the mature brain. In addition,
radial growth of the Ts16 cortex was delayed probably due
to a defective cortical neurogenesis, since the number of
neocortical founder cells is reduced by 26% in Ts16 mice,
leading to a reduction in overall cortical size at the end of
Ts16 neuronogenesis (Haydar et al., 2000). Thus, altered
proliferative characteristics during Ts16 neuronogenesis
result in a delay in the generation of neocortical neurons,
whereas the founder cell deficit leads to a proportional
reduction in the overall number of neurons. Such prenatal
perturbations in either the timing of neuron generation or
the final number of neurons produced may lead to
significant neocortical abnormalities such as those found
in DS (Haydar et al., 1996, 2000).
More recently three partial trisomic mice of MMU16
became available (see Gardiner et al., 2003 for review):
Ts65Dn mice (Davisson et al., 1990) contain three copies of
MMU16 from App to Mx1; Ts1Cje mice have three copies
from Sod1 to Mx1 and Ms1Ts65 (Sago et al., 1998) App to
Sod1. The generation by Davisson et al. (1990) of a partial
trisomy 16 mouse, the Ts (1716) 65Dn or Ts65Dn model, that
includes most of the MMU16 region homologous to HSA21
(from App to Mx1) but which lacks the remaining
approximately 40% of HSA21 genes (Akeson et al.,
2001) has lead to a major advance in DS research. Although
many genes overexpressed in Ts65Dn are homologous to
those included in the DSCR, these mice do not show some of
the gross abnormalities frequently observed in DS, such as
cardiac valvular congenital abnormalities (Montero et al.,
1996). However, Ts65Dn mice exhibit analogous effects on
craniofacial structures and cognitive deficits (Escorihuela et
al., 1995, 1998; Richtsmeier et al., 2000; Holtzman et al.,
1996; Hyde and Crnic, 2002; Hunter et al., 2003; Wenger et
al., 2004). In terms of behaviour, the Ts65Dn mice show
deficits in reference and working memory that correlate with
frontal cortex BDNF levels (Bimonte-Nelson et al., 2003),
hyperactivity, reduced attention levels (Escorihuela et al.,
1995, 1998; Reeves et al., 1995; Coussons-Read and Crnic,
1996; Holtzman et al., 1996; Hyde et al., 2001), and reduced
responsiveness to nociceptive stimuli (Martı´nez-Cue´ et al.,
1999). Although brain size and histology appear normal in
Ts65Dn mice, significant alterations have been reported;
high-resolution magnetic resonance imaging and histologi-
cal analysis reveal neuroanatomical parallels between DS
and Ts65Dn cerebellum (Baxter et al., 2000). Cerebellar
volume is decreased in Ts65Dn mice due to reductions in
both the internal granule layer and the molecular layer.
Granule cell number also is decreased. The cerebellar
dysmorphology in the Ts65Dn mouse parallels that of DS
individuals, and may be related to the global disruption of
the cerebellar transcriptome (Saran et al., 2003). In addition,
stereological morphometric studies demonstrate minor
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Fig. 2. Camera lucida drawings of layer III pyramidal neurons, as seen in the plane of section parallel to the cortical surface, sampled from wild type and
Ts65Dn+/ mice. Illustrated cells have basal dendritic arbours that approximated the average size in each of the groups. Scale bar = 150 mm.irregularities in selected regions of the hippocampus of
Ts65Dn mice, including reductions in the volume of CA2
and in neuronal density in the dentate gyrus (Insausti et al.,
1998).
Of particular interest is the structure of pyramidal cells,
the most ubiquitous neuron in the neocortex. Using
intracellular injections with Lucifer Yellow to visualize
the whole basal dendritic tree, we find that pyramidal cells
are smaller, less branched and 24% less spinous in Ts65Dn
mice than those in controls (Fig. 2). These effects on
pyramidal cell structure parallel those obtained in humans
(see Section 2). The similarity of the structural changes in
the Ts65Dn mice to those in DS, indicate that this model will
provide a means by which to study brain pathology in DS not
possible in humans (see Section 2). More specifically, the
Ts65Dn mouse provides a vehicle in which to study themicroanatomical substrate of mental retardation in DS, and
develop new treatment strategies.
Our group has combined dendritic labelling and synapse
analysis in Ts65Dn mice. At old ages, the temporal cortex of
Ts65Dn mice has a significantly lower number (30%) of
asymmetric (presumptive excitatory) synapses while the
number of symmetric (presumptive inhibitory) synapses is
not different than controls (Kurt et al., 2000). However, the
mean synaptic apposition lengths of both asymmetric and
symmetric synapses were significantly larger in Ts65Dn
mice (15 and 11%, respectively), suggesting that excitatory
synapses are preferentially affected in Ts65Dn mice and that
there is an attempt to compensate for the deficit of
asymmetric synapses by increasing the contact zone area
of existing synapses. Neurochemical studies have revealed
abnormal patterns in signalling pathways involved in
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growth. Adenyl cyclase and phospholipase C signalling
pathways are also severely disturbed in the brain of Ts65Dn
mice and patients with DS (Dierssen et al., 1996, 1997; Ruiz
de Azua et al., 2001). These alterations may lead to
functional abnormalities in the central nervous system since
both basal and stimulated production of cyclic AMP (cAMP)
are reduced in Ts65Dn mice.
In addition, studies investigating alterations of neuro-
transmitters, synaptic ultrastructure, and long-term poten-
tiation demonstrate severe deficits in the limbic system of
Ts65Dn mice (Siarey et al., 1997). Behavioural studies
confirm deficiencies observed at a molecular level, showing
that Ts65Dn mice perform poorly on tasks requiring spatial
memory, including the Morris maze, the land version
of the radial-arm maze (RAM), and context discrimination
tasks.
The results of studies of cultured neurons from human
foetuses with DS and from foetuses of animal models for
DS suggest that the malfunctioning of brain circuits in the
DS brain may arise from abnormal neuronal electrical and
biochemical properties, since long-term memory storage
depends on morphological and biochemical changes
associated with experience-dependent plasticity of neuro-
nal synapses. Changes in spine number and morphology
reflect mechanisms for converting transient changes in
synaptic activity into long-lasting memory. In Ts65Dn
mice, abnormalities in the duration of the action potential
and its rates of depolarisation and repolarisation, altered
kinetics of active Na+, Ca2+ and K+ currents, and altered
membrane densities of Na+ and Ca2+ channels have been
observed (see Galdzicki and Siarey, 2003 for review).
Furthermore, electrophysiological studies of the CA1
region of the hippocampus from the adult Ts65Dn mouse
show synaptic plasticity changes that lead to abnormalities
in LTP and LTD, models of learning and memory (Siarey et
al., 1999; Galdzicki and Siarey, 2003).
Ts1Cje is another partial trisomy 16 mouse model for
Down syndrome that exhibits learning and behavioural
abnormalities (Sago et al., 1998). The Ts1Cje mouse
contains a translocated chromosome 16, and is at dosage
imbalance for 67% of the genes triplicated in Ts65Dn. It has
been attempted to assess the phenotypic contribution of the
region of difference between Ts65Dn, Ts1Cje, and a new
segmental trisomic (Ms1Ts65) for the region of difference
(APP to Sod1) by generating these models as littermates and
testing them in parallel. Whereas triplication of Sod1 to Mx1
plays the major role in causing the abnormalities of Ts65Dn
in the Morris water maze, imbalance of APP to Sod1 also
contributes to the poor performance, so that although the
performance of Ts1Cje mice was similar to that of Ts65Dn
mice, Ts65Dn was more severely affected in the reverse
probe tests. By contrast, the deficits of Ms1Ts65 mice were
significantly less severe than those of Ts65Dn (Sago et al.,
2000). However, although this first report indicated a
dosage-imbalance effect in learning and memory, subse-quent work on other phenotypes gave rise to contradictory
results. Trisomic mice have cerebellar pathology with direct
parallels to DS. When studying the cerebellar phenotypes in
detail, by comparing the three available trisomic models,
cerebellar volume was significantly affected to the same
degree in Ts1Cje and Ts65Dn, despite that Ts1Cje has fewer
triplicated genes. However, dosage imbalance in Ts1Cje had
little effect on granule cell and Purkinje cell density. Several
mice with dosage imbalance for the segment of the Ts65Dn
chromosome not triplicated in Ts1Cje had phenotypes that
contrasted with those in Ts1Cje (Olson et al., 2004). These
observations point to specific gene action in DS more than a
general dosage-imbalance effect.4. Pharmacological and non-pharmacological strategies
targeting cognitive functions treatments: can we
change Down syndrome brains?
4.1. Drugs to improve cognition
Over the years a wide range of therapies to improve
cognition in persons with DS have been studied. At present,
there is no proven pharmacological treatment for the
cognitive or language impairments in DS. Different
strategies for the treatment of cognitive deficits in DS have
been employed. Dietary supplements such as vitamins and
minerals have been proposed to increase the intelligence
coefficient in subjects with DS. These approaches are based
on the premise that a biochemical imbalance exists in DS.
However, recent reviews clearly show no effectiveness of
vitamin or mineral supplement in any of the included trials
(Salman, 2002; Roizen and Patterson, 2003). Given what is
now known regarding the critical periods for synaptic
development and the organisation of large-scale neuronal
circuits in the developing cerebral cortex, it appears that
there may exist a window of opportunity during which
specifically targeted, pharmacologic intervention could
exert a significantly favourable biologic effect during
development. Pharmacologic agents that increase the brain’s
responsiveness to activity-dependent plasticity may be of
particular therapeutic benefit to children with some forms of
mental retardation. Currently available medications have
targeted cholinergic neurotransmission and to a lesser
degree glutamatergic neurotransmission, both of which play
important roles in learning, memory, and developmental
organisation of the brain.
Enhancement of electrochemical signalling in the brain is
based on chemical facilitation of existing synaptic function
and is considered to be of short-term benefit. Current
pharmacologic strategies, including nootropic drugs such
piracetam, a cyclic derivative of gamma amino butyric acid
(GABA), are claimed to improve the efficiency of higher
order functions in the brain that are involved in cognitive
processes such as learning and memory. In addition, based
on studies in animals demonstrating synergistic effects of
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treatment has been recommended for DS. However, the first
formal assessment of the efficacy of piracetam in DS has not
been positive (Lobaugh et al., 2001). Results from a recently
reported double-blind, placebo-controlled, crossover study
of the efficacy of piracetam for increasing cognitive
functioning in DS have shown not only that piracetam
treatment did not enhance cognitive performance but also
that it was associated with a number of adverse effects in
children with DS. More recently, the efficacy of piracetam
treatment has been explored in Ts65Dn mice, and after
cognitive evaluation, the data reveal no support for the
treatment of individuals with DS (Moran et al., 2002).
The ‘‘cholinergic hypothesis’’ of memory dysfunction
has done much to focus research efforts on cholinergic
strategies for the enhancement of learning and memory.
Medications that affect cholinergic neurotransmission
include acetylcholine precursors, acetylcholinesterase inhi-
bitors, and muscarinic agonists. DS is associated with early
dementia with similarities in pathology and biochemistry to
AD, providing a rationale for the use of cholinesterase
inhibitors (see Gustavson and Cummings, 2003). There is a
known loss of cholinergic neurons providing input to limbic
structures and cortex in both AD and DS. There is
accumulation of abnormal beta-amyloid in both disorders,
which presumably causes neuronal death and hence a
presynaptic deficit. Cholinesterase inhibitors can be
predicted to be helpful in this disorder and are beneficial
for some of the cognitive and functional deficits associated
with AD. However, despite considerable theoretical reasons
to suggest patients with DS, especially those with concurrent
dementia, could derive benefit from cholinesterase inhibitor
therapy, there are currently few studies reported in the
literature from which to draw a conclusion. Some authors
claim improvement in socialisation subscale and adaptive
behaviour composite score (Kishnani et al., 1999) in patients
with DS with or without dementia (Lott et al., 2002; Prasher
et al., 2002). Others report no clinical benefit and frequent
adverse effects (Cipriani et al., 2002; Hemingway-Eltomey
and Lerner, 1999). Recently, adults with DS were treated
with donepezil as a therapy for language deficits. The results
indicate an improvement in expressive language perfor-
mance in patients with DS (Heller et al., 2003).
Tests of various hormone therapies, including thyroid,
steroid and growth hormone have yielded only poor results.
However, a recent study carried out in Ts65Dn mice
indicates that estrogen treatment can restore cognition and
cholinergic phenotype. The authors show that female mice
(11–15 months) that received a subcutaneous estrogenic
pellet improved learning of a T-maze task and normalized
behaviour in reversal learning of the task, a measure of
cognitive flexibility (Granholm et al., 2000). Moreover, the
total number of cholinergic neurons in the medial septum,
identified by alterations in amyloid precursor protein as well
as dendritic and cholinergic markers, increased (Granholm
et al., 2002, 2003). The authors suggest that estrogenictreatment might be a viable therapeutic approach for women
with DS coupled with dementia.
Drugs targeting the glutamatergic system are among
the most novel modalities in treating disorders of memory
and learning. These drugs have grown in proportion to
advancements in our understanding of the physiologic and
pathologic alterations underlying mental retardation.
Animal models of memory formation indicate that
synaptic events lead to an intracellular cascade involving
calcium fluxes, a variety of protein kinases, and activation of
transcription factors and immediate early genes such as c-
Fos, c-Jun and Zif-268 (see Rose, 2002 for review). An
important step in this sequence involves the cyclic-AMP-
responsive-element-binding protein (CREB), which is
implicated in memory formation in both Drosophila and
mice. However, the ability of these interventions to enhance
human memory through facilitation on synaptic activity-
dependent events remains speculative at present.
Although gene therapy for DS is probably years down the
road, it holds great promise for increasing the specificity of
treatments while reducing unnecessary or dangerous side
effects. In DS, where overexpression of a number of genes
exists, gene therapy approaches will have to focus in
reducing gene expression. As we begin to understand the
function of specific genes and identify the contribution of
individual genes to the overall phenotype, partial gene
therapy for specific defects could be a good approach. One
of the main caveats for gene therapy is that it requires a
technology capable of gene transfer in a wide variety of
cells, tissues and whole organs. To date, antisense
oligonuceotides or ribozymes were the only available tools
for reducing gene expression. Several in vivo studies have
shown that antisense oligonucleotides directly delivered to
the brain of animals modify behaviour (Zapata et al., 1997;
Persico et al., 1998). This finding strongly supports the
proposal that reducing gene expression by gene therapy
approaches has the potential to treat disorders associated
with gene overexpression in the CNS. Although still not
optimum, several delivery vectors are available to introduce
genes (Somia and Verma, 2000). Highly efficient systems,
such as adenovirus, adeno-associated virus and more
recently lentivirus, deliver genes into mature neurons
both in vivo and in vitro, allowing the design of gene
therapies for brain diseases (Costantini et al., 2000). A
novel, very powerful gene silencing mechanism, RNA
interference (RNAi), recently was discovered. Gene therapy
approaches that are being developed that are based on this
technology hold great promise for targeting candidate
overexpressed genes in DS (McManus and Sharp, 2002;
Song et al., 2003).
4.2. Non-pharmacological strategies
Early implementation of special education programs
leads to improved cognitive abilities in individuals with DS
(Connolly et al., 1993; Foreman and Manning, 1986) but the
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ary. The neural correlates of the temporary effects are
unknown. Animals reared in enriched environments out-
perform conspecifics in learning, memory and visual acuity,
suggesting that circuits are modified in order to optimise
multiple levels of information processing and storage
(Fernandez-Teruel et al., 1997; Prusky et al., 2000).
Structural differences in the cerebral cortex are thought to
underpin these behavioural improvements. Past studies of
the intact brain using Golgi impregnated material correlate
changes in dendritic spine morphology with development,
enriched environment and aging. The rationale for these
studies is that alterations in these conditions would exert
major changes in brain structure and function (Rosenzweig
et al., 1972; Volkmar and Greenough, 1972; Globus et al.,
1973). These studies show that experience correlates with an
increase in the spine density, in the complexity of dendritic
arbourisation and in the length of cortical dendrites.
Recently, the effect of enriched environment applied to
pups for 7 weeks after weaning upon behavioural and
cognitive performances was assessed in partially trisomic
Ts65Dn mice. Exposure to complex environments modu-
lated behaviour and spatial memory in Ts65Dn and euploid
mice (Martinez-Cue et al., 2002). Moreover, the effects on
behaviour were sex-specific. Environmental enrichment
induced a slight but significant improvement of performance
in Ts65Dn females but worsened performance in Ts65Dn
male mice in the Morris water maze. These results indicate
that gender is a factor that impacts this behavioural
intervention (Martinez-Cue et al., 2002).
In our experimental design (Dierssen et al., 2003),
euploid, non-trisomic mice exposed to an enriched
environment showed increases in dendritic complexity
and in the number of spines. These effects could account
for the better performance on some of the behavioural tasks.
However, environmental enrichment did not alter the spine
density or the number of spines in Ts65Dn mice. These
results suggest that the molecular pathways that mediate
neuronal reinforcement in the early stages of pruning might
be affected by the partial trisomy of MMU16, resulting in
different behavioural and cognitive abilities. Despite the
marked differences in the number of spines found on the
dendritic arbours of pyramidal cells in the different
experimental groups, the distribution of the spines through-
out the arbours remains remarkably similar (Elston and
DeFelipe, 2002).
Mechanisms that determine spine morphology remain
controversial. In cortex, it has been suggested that processes
which lead to shrinkage and elongation of dendritic spines
are controlled locally. In contrast, processes leading to the
formation of novel spines may extend beyond local
biochemical events (Smart and Halpain, 2000) or may be
engineered centrally, through messages arriving from the
soma, where a global increase in dendritic spine density is
seen after a nuclear message (phosphorylation of CREB)
(see Segal, 2001 for review).Recently it has been documented that levels of
neurotrophic factors such as BDNF increase in the central
nervous system in response to enhanced environmental
complexity (Falkenberg et al., 1992; Ickes et al., 2000; Pham
et al., 1999; Torasdotter et al., 1998). Levels of BDNF are
altered in Ts65Dn mice and in children with DS
(Calamandrei et al., 2000). This neurotrophic factor impacts
the survival of the basal prosencephalon cholinergic nucleus
(Cooper et al., 2001; Delcroix et al., 2004). Other candidate
molecules that guide morphological restructuring, synapto-
genesis, and synaptic weighing and that control the plastic
changes induced by environmental enrichment in the CNS
(Rampon et al., 2000) may also be affected in this DS model.
Thus, the behavioural consequences of enrichment observed
in the Ts65Dn mice may not be entirely the result of the
structural reorganisation of the pyramidal cells of the frontal
cortex. Since stable long-term changes in spines are involved
in the formation of stable memories, it might be argued that
the less-stable behavioural effects of environmental enrich-
ment could be dependent on more transient effects on
functional synaptic mechanisms.5. Conclusions
This paper addresses the mechanisms that cause mental
deficiency in Down syndrome and the enduring question of
the relationship between structure and function in the
cerebral cortex. DS is associated with several brain
abnormalities including altered cortical volume, stratifica-
tion, dendritic atrophy, cellular differentiation and synaptic
dysgenesis during the post-natal period. Some of these
changes, such as dendritic alterations are also present in
other cognition disorders and have been proposed as the
most consistent anatomopathological feature of mental
retardation. A better understanding of DS neuronal networks
is essential to understand the alterations of cognitive
processes, and to achieve this goal animal models have
enormous potential to elucidate mental retardation mechan-
isms that may be acting in humans. Animal models can
overcome many of the limitations inherent in studies of
human patients, such as rarity of the disease, extremely
complex genetic background and logistical and ethical
constraints in the design and execution of experiments with
human subjects. To date, these models have helped in the
clarification of the pathophysiology/pathogenetic mechan-
ism of disease and they will serve the exploration of
therapeutic approaches in the near future. Studies with the
various animal models of DS at different developmental
stages have recreated certain conditions that result in
abnormal learning capabilities in DS, and previous work has
found abnormalities of cortical volume, lamination, pro-
liferation and connectivity. We propose that some genes are
major candidates to explain the dendritic spine functional
and structural alteration. These genes will most probably be
those who have been proven to produce a dosage-dependent
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may lead to changes in timing and synaptic interaction
between neurons during development, which can lead to less
than optimal functioning of neural circuitry and signalling at
that time and in later life.Acknowledgments
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